Israel - English - Ministry of Health

david margalit & co.ltd - octreotide as acetate - solution for injection - octreotide as acetate 0.05 mg/ml - octreotide - prevention of complications following pancreatic surgery. symptomatic control and reduction of gh and igf-1plasma levels in patients with acromegaly who are inadequately controlled by surgery or radiotherapy.octreotide bendalis treatment is also indicated for acromegalic patients unfit or unwilling to undergo surgery or in the interim period until radiotherapy becomes fully effective. relief of symptoms associated with functional gastroenteropancreatic endocrine tumours: - carcinoid tumours with features of the carcinoid syndrome. - vipomas . - glucagonomas . - gastrinomas / zollinger-ellison syndrome usually in conjunction with proton pump inhibitors or h2- antagonist therapy . - insulinomas for pre-operative control of hypoglycaemia and for maintenance therapy . - grfomas. - octreotide bendalis is not an antitumour therapy and is not curative in these patients.emergency management of bleeding gastro-oesophageal varices secondary to cirrhosis in combination with specific therapy such as endoscopic sclerotherapy.

Israel - English - Ministry of Health

david margalit & co.ltd - octreotide as acetate - solution for injection - octreotide as acetate 0.1 mg/ml - octreotide - prevention of complications following pancreatic surgery. symptomatic control and reduction of gh and igf-1plasma levels in patients with acromegaly who are inadequately controlled by surgery or radiotherapy.octreotide bendalis treatment is also indicated for acromegalic patients unfit or unwilling to undergo surgery or in the interim period until radiotherapy becomes fully effective. relief of symptoms associated with functional gastroenteropancreatic endocrine tumours: - carcinoid tumours with features of the carcinoid syndrome. - vipomas . - glucagonomas . - gastrinomas / zollinger-ellison syndrome usually in conjunction with proton pump inhibitors or h2- antagonist therapy . - insulinomas for pre-operative control of hypoglycaemia and for maintenance therapy . - grfomas. - octreotide bendalis is not an antitumour therapy and is not curative in these patients.emergency management of bleeding gastro-oesophageal varices secondary to cirrhosis in combination with specific therapy such as endoscopic sclerotherapy.

Israel - English - Ministry of Health

david margalit & co.ltd - octreotide as acetate - solution for injection - octreotide as acetate 0.2 mg/ml - octreotide - prevention of complications following pancreatic surgery. symptomatic control and reduction of gh and igf-1plasma levels in patients with acromegaly who are inadequately controlled by surgery or radiotherapy.octreotide bendalis treatment is also indicated for acromegalic patients unfit or unwilling to undergo surgery or in the interim period until radiotherapy becomes fully effective. relief of symptoms associated with functional gastroenteropancreatic endocrine tumours: - carcinoid tumours with features of the carcinoid syndrome. - vipomas . - glucagonomas . - gastrinomas / zollinger-ellison syndrome usually in conjunction with proton pump inhibitors or h2- antagonist therapy . - insulinomas for pre-operative control of hypoglycaemia and for maintenance therapy . - grfomas. - octreotide bendalis is not an antitumour therapy and is not curative in these patients.emergency management of bleeding gastro-oesophageal varices secondary to cirrhosis in combination with specific therapy such as endoscopic sclerotherapy.

Israel - English - Ministry of Health

david margalit & co.ltd - octreotide as acetate - solution for injection - octreotide as acetate 0.5 mg/ml - octreotide - prevention of complications following pancreatic surgery. symptomatic control and reduction of gh and igf-1plasma levels in patients with acromegaly who are inadequately controlled by surgery or radiotherapy.octreotide bendalis treatment is also indicated for acromegalic patients unfit or unwilling to undergo surgery or in the interim period until radiotherapy becomes fully effective. relief of symptoms associated with functional gastroenteropancreatic endocrine tumours: - carcinoid tumours with features of the carcinoid syndrome. - vipomas . - glucagonomas . - gastrinomas / zollinger-ellison syndrome usually in conjunction with proton pump inhibitors or h2- antagonist therapy . - insulinomas for pre-operative control of hypoglycaemia and for maintenance therapy . - grfomas. - octreotide bendalis is not an antitumour therapy and is not curative in these patients.emergency management of bleeding gastro-oesophageal varices secondary to cirrhosis in combination with specific therapy such as endoscopic sclerotherapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - octreotide acetate 11.2mg equivalent to octreotide 10 mg;   - powder for injection - 10 mg - active: octreotide acetate 11.2mg equivalent to octreotide 10 mg   excipient: mannitol polyglactin carmellose sodium mannitol poloxamer water for injection carmellose sodium mannitol water for injection - treatment of patients with acromegaly: · in whom surgery or radiotherapy is inappropriate or ineffective, or in the interim period until radiotherapy becomes fully effective. treatment of patients with symptoms associated with functional gastro-entero-pancreatic endocrine tumours: · carcinoid tumours with features of the carcinoid syndrome. · vipomas · glucagonomas · gastrinomas/zollinger-ellison syndrome · insulinomas, for pre-operative control of hypoglycaemia and for maintenance therapy. · grfomas

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - octreotide acetate 22.4mg equivalent to octreotide 20 mg;   - powder for injection - 20 mg - active: octreotide acetate 22.4mg equivalent to octreotide 20 mg   excipient: mannitol polyglactin carmellose sodium mannitol poloxamer water for injection carmellose sodium mannitol water for injection - treatment of patients with acromegaly: · in whom surgery or radiotherapy is inappropriate or ineffective, or in the interim period until radiotherapy becomes fully effective. treatment of patients with symptoms associated with functional gastro-entero-pancreatic endocrine tumours: · carcinoid tumours with features of the carcinoid syndrome. · vipomas · glucagonomas · gastrinomas/zollinger-ellison syndrome · insulinomas, for pre-operative control of hypoglycaemia and for maintenance therapy. · grfomas

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - octreotide acetate 33.6mg equivalent to octreotide 30 mg;   - powder for injection - 30 mg - active: octreotide acetate 33.6mg equivalent to octreotide 30 mg   excipient: mannitol polyglactin carmellose sodium mannitol poloxamer water for injection carmellose sodium mannitol water for injection - treatment of patients with acromegaly: · in whom surgery or radiotherapy is inappropriate or ineffective, or in the interim period until radiotherapy becomes fully effective. treatment of patients with symptoms associated with functional gastro-entero-pancreatic endocrine tumours: · carcinoid tumours with features of the carcinoid syndrome. · vipomas · glucagonomas · gastrinomas/zollinger-ellison syndrome · insulinomas, for pre-operative control of hypoglycaemia and for maintenance therapy. · grfomas

New Zealand - English - Medsafe (Medicines Safety Authority)

max health limited - octreotide acetate 0.112 mg/ml equivalent to octreotide 100 mcg/ml - solution for injection - 100 mcg/ml - active: octreotide acetate 0.112 mg/ml equivalent to octreotide 100 mcg/ml excipient: glycine hydrochloric acid mannitol water for injection - symptomatic control and reduction of growth hormone (gh) and igf-1 plasma levels in patients with acromegaly who are inadequately controlled by surgery or radiotherapy. octreotide treatment is also indicated for acromegalic patients unfit or unwilling to undergo surgery, or in the interim period until radiotherapy becomes fully effective.

New Zealand - English - Medsafe (Medicines Safety Authority)

max health limited - octreotide acetate 0.056 mg/ml equivalent to octreotide 50 mcg/ml - solution for injection - 50 mcg/ml - active: octreotide acetate 0.056 mg/ml equivalent to octreotide 50 mcg/ml excipient: glycine hydrochloric acid mannitol water for injection - symptomatic control and reduction of growth hormone (gh) and igf-1 plasma levels in patients with acromegaly who are inadequately controlled by surgery or radiotherapy. octreotide treatment is also indicated for acromegalic patients unfit or unwilling to undergo surgery, or in the interim period until radiotherapy becomes fully effective.

New Zealand - English - Medsafe (Medicines Safety Authority)

max health limited - octreotide acetate 0.56 mg/ml equivalent to octreotide 500 mcg/ml - solution for injection - 500 mcg/ml - active: octreotide acetate 0.56 mg/ml equivalent to octreotide 500 mcg/ml excipient: glycine hydrochloric acid mannitol water for injection - symptomatic control and reduction of growth hormone (gh) and igf-1 plasma levels in patients with acromegaly who are inadequately controlled by surgery or radiotherapy. octreotide treatment is also indicated for acromegalic patients unfit or unwilling to undergo surgery, or in the interim period until radiotherapy becomes fully effective.